Abstract
drugs. While increased resistance to other drugs (positive cross-resistance) is 39 common 5, 6 , for some drug pairs, resistance to one drug decreases resistance to another 40 drug (negative cross-resistance, also called collateral sensitivity 7 ). Systematic studies 41 have revealed specific drug pairs with negative cross-resistance, including cases of 42 reciprocal negative interactions, whereby resistance to any of the two drugs confers 43 sensitivity to the other [4] [5] [6] 14 . Simultaneous use of drug pairs with negative cross 44 resistance has been explored as a means to slow down the evolution of resistance to 45 toxins ranging from antibiotics to pesticides [5] [6] [7] [15] [16] [17] [18] . Alternatively, drugs with collateral 46 sensitivity can be used sequentially to slow evolution of resistance, thus avoiding toxicity 47 or incompatibility issues that complicate antibiotic mixtures in clinical settings 5, 7 . 48
It remains unknown whether the effectiveness of alternating negative cross-resistance 49 treatment is robust to the large population size often found in clinical infections, and to 50 what extent longer-term evolution can be reliably predicted by the cross-resistance 51 profiles of first-step mutants. Previous measurements on negative cross-resistance have 52 typically assayed a small number of first-step mutants, and evolution experiments were 53 conducted with small population sizes [5] [6] [7] 9, 19, 20 . Because the diversity of cross-resistance 54 across random mutants has not been systematically measured, it is unknown whether 55 negative cross-resistance seen in typical mutants is representative, and whether 56 negative cross-resistant treatment would be effective for larger populations with larger 57 potential for rare mutants. 58
We focus here on Staphylococcus aureus, a common human pathogen in which de novo 59 antibiotic resistance is of clinical importance [21] [22] [23] [24] [25] . We developed a high-throughput assay 60 to profile the cross-resistances of 3317 resistant mutants to six antibiotics with diverse 61 mechanisms of action: oxacillin (OXA), novobiocin (NOV), ciprofloxacin (CPR), 62 gentamicin (GEN), amikacin (AMK), and doxycycline (DOX) ( Fig. 1a ; Supplementary 63 Table 1 ). 64
The frequency of surviving colonies as a function of antibiotic concentration follows a 65 characteristic shape: survival falls off when drug concentration exceeds the minimum 66 inhibitory concentration (MIC), and then plateaus around 10 -6 -10 -8 until it drops below 67 detection at drug concentrations high enough to kill even the most resistant mutant 68 (Mutant Prevention Concentration, MPC) 26 . The plateau region between the MIC and 69 MPC is termed the mutant selection window (MSW), and constitutes the range of 70 antibiotic concentrations where selection for resistance occurs. For each antibiotic, we 71 collected roughly 500 resistant mutants from plates in the MSW range ( Fig. 1a; 
72
Supplementary Fig. 1 ; Methods). We measured the level of resistance of each of 73 these mutants to each of the 6 antibiotics by growing the library on a series of agar 74 plates at increasing antibiotic concentrations ( Fig. 1b; Methods) . Positive cross-75 resistance was detected when a mutant survived at higher drug concentrations than the 76 wild-type, while negative cross-resistance was indicated by the wild-type growing at a 77 higher drug concentration than the mutant. (Fig. 1b) . Using a robotic pipeline, we 78 systematically measured cross-resistance interactions in nearly 20,000 mutant-drug 79 combinations. 80 Cross-resistance 3x10 3 3x10 2 20 4x10 4 Fig. 1 . High-throughput measurement of cross-resistance in 3,317 de novo mutants reveal considerable diversity in both the magnitude and sign of cross-resistance. a) The mutant selection window for NOV was measured by counting the frequency of survivors at 10 drug concentrations. Each line indicates an independent biological replicate. Inserts show examples from the automated imaging pipeline. b) Measured resistance to NOV and cross-resistance to CPR of mutants selected on NOV, showing a range of MICs for both drugs. Examples of the automated image pipeline are shown for two isolates (1 and 2), chosen as indicated from the inset in (a). c) The network of most frequently seen cross-resistance interactions between every drug pair in our library. The majority of pairs show positive cross-resistance. Only the most common phenotype out of three possible phenotypes (positive, negative, and neutral crossresistance) representing a plurality (>33%) of all mutants are shown. The one reciprocal negative cross-resistant pair, OXA and NOV, is highlighted. d) The full network of cross-resistance for all observed mutants, showing heterogeneous interactions for all pairs. Here every mutant is represented as a single edge originating from the drug it was selected in. and other antibiotics (Fig. 1c) . These observations highlight the species-specificity of 89 cross-resistance interactions, and indicate that cross-resistance-based treatment 90 strategies must be tailored for specific organisms. 91
Cross-resistance profiles are highly heterogeneous 92
Analysis of the distribution of cross-resistance reveals that, for all drug pairs, there is 93 considerable variation in magnitude and sign of cross-resistance among the collection of 94 resistant mutants. Even for drug pairs where mutants primarily display cross-resistance 95 of a specific sign, there are rare mutants with phenotypes opposite to the general trend 96 ( Fig. 1d; Supplementary Fig. 2a ). The MICs of the two aminoglycosides, AMK and 97 GEN, were positively correlated, however we observed no strong MIC correlations 98 between antibiotic pairs from different classes (Supplementary Fig. 3 ). Going beyond 99 the typical measurements of small numbers of resistant mutants revealed hitherto 100 unseen diversity in cross-resistance profiles (Supplementary Fig. 3 ). 101
To investigate the impact of diversity in cross-resistance, we focused on the reciprocal 102 negative cross-resistance pair OXA and NOV (Fig. 1b) . While for the majority of OXA 103 and NOV resistant mutants, negative cross-resistance to the other drug was observed, 104 rare, positive cross-resistant mutants also appear (Fig. 2) . Of the OXA-resistant 105 mutants, 74% have negative cross-resistance to NOV, 21% do not affect NOV 106 resistance, while 5% have positive cross-resistance. Of the NOV-resistant mutants, 62% 107 exhibit negative cross-resistance to OXA, 33.5% do not affect OXA resistance and 4.5% 108 display positive cross-resistance. These observations suggest that while small-scale 109 studies may identify OXA and NOV as a reciprocal negative cross-resistance pair, they 110 would miss the underlying fraction of rare mutants with positive cross-resistance, which 111 could in turn affect the evolution of multi-drug resistance. 112
Rare mutants appearing in large populations reverse the outcome of cycling 113 We next asked whether rare cross-resistant phenotypes can impact the effectiveness of 114 negative cross-resistance treatments. As rare positive cross-resistant mutants are more 115 likely to appear in larger populations, we hypothesized that the outcome of sequential 116 treatment with a reciprocal negative cross-resistance drug pair would be affected by 117 population size. We first considered treatment with OXA followed by NOV, followed by 118 the reciprocal. Based on the measured frequencies of resistance ( Supplementary Fig.  119 1), we selected for resistant mutants at the same concentration from either a small (10   6   120 cells) inoculum, in which approximately one mutant is expected to survive, and a large 121 (10 9 cells) inoculum, in which approximately a thousand mutants are expected to survive. 122
After selection for resistance to the first drug, we expanded the two populations to the 123 same size, and measured the frequency of survivors as a function of the concentration of 124 the second drug, as compared to the ancestral wildtype (Methods, Fig. 3a) . 125
While the low-inoculum OXA-evolved population exhibited marked negative cross-126 resistance to NOV, the high-inoculum population displayed not only a reduction but a 127 complete inversion of this negative cross-resistance (Fig. 3b) . The MIC of the low-128 inoculum population is reduced in comparison to the WT, demonstrating the efficacy of 129 negative cross-resistance in using one drug in order to reduce resistance to another 130 (fewer than one in 10 5 survivors at 0.15 ng/mL NOV compared to WT 0.36 ng/mL). 131
Beyond a reduction in MIC, this low-inoculum population also has lower potential to 132 evolve as evident by its significantly reduced MPC (1.1 ng/mL NOV for the OXA-evolved 133 population vs 4.0 ng/mL for the WT). In striking contrast, the population that was 134 selected on the same exact drug concentration of OXA but with large inoculum size 135
showed an increase rather than decrease in resistance (fewer than one in 10 5 survivors 136 at 0.86 ng/mL). Further, unlike the low-inoculum population, the high-inoculum 137 population has the same MPC as the wild type, showing no reduction in evolutionary 138
potential. The reciprocal case of NOV followed by OXA resulted in similar, albeit less 139 ) and selected in identical concentrations of OXA. The two populations, along with the ancestor, were then grown to the 1e9 cells/mL before plating on NOV. b) The low diversity population (dashed red line) exhibits negative cross-resistance. However, the high diversity population (solid red line), which differs from the low diversity population only in the starting population size, exhibits positive cross resistance. c) NOV-resistance profiles of colonies were picked from the high and low inoculum populations after selection in oxacillin. The low inoculum population (L) show primarily negative cross-resistance to NOV, while the high inoculum population (H) displays a much more diverse cross-resistance profile, including rare mutants that have positive cross-resistance to NOV. drastic, inversion of negative cross-resistance due to inoculum size (Supplementary 140 Fig. 4a) . 141
Phenotyping mutants recovered after liquid selection, we found that the low inoculum 142 population shows homogenous negative-cross resistance phenotypes while the high 143 inoculum population is more diverse and contains rare positive cross-resistance mutants. 144
Isolation of colonies from the low diversity population after OXA selection but before 145 NOV selection shows a relatively homogenous population with negative cross-resistance 146 to NOV (Fig. 3c, L) . In contrast, colonies from the high inoculum population before NOV 147 selection shows a wider spread of cross-resistance phenotypes (Fig. 3c, H) . Only 1% of 148 this high inoculum population showed positive cross-resistance with 2.4-fold increase in 149 MIC over the wild type (Fig. 3c, H Negative cross resistance is not preserved through sequential antibiotic selection 186 Our results suggest that negative cross-resistance cycling may be more successful if the 187 population size was kept small at each step. To study whether maintenance of small 188 population size is sufficient for success of negative cross-resistance cycling, we 189 sequentially treated populations with OXA and NOV, transferring 10 6 or 10 7 cells at each 190 step for OXA and NOV selection, respectively, to limit diversity based on the frequency 191 of mutation (Fig. S1) . We found that the first step consistently produces negative cross-192 resistance. However, as mutations accumulate in subsequent steps, negative cross-193 resistance frequently disappeared (Fig. 4) 
Methods

219
Media, strain, and antibiotics. The ancestral strain used for all experiments is 220
Staphylococcus aureus RN4220, a phage-free strain derived from NCTC 8325 35 . 221
Independent cultures of the ancestor were inoculated with single colonies, grown 222 overnight at 37°C, and stored in 16.7% (v/v) glycerol at -80°C. All experiments were 223 conducted in either trypticase soy agar (TSA, BD 211046) or trypticase soy broth (TSB, 224 BD 211771). Antibiotic solutions were prepared from powder at 10mg/ml in water and 225 stored at 4°C (unless otherwise specified): Oxacillin (Sigma 28221); Novobiocin (Sigma 226 N6160); Ciprofloxacin (Sigma 17850), in 100mM HCl; Doxycycline (Sigma 09891); 227
Gentamycin (Sigma G1264), 50mg/ml; Amikacin (Sigma A1774), 50mg/ml. 228
Evolution of first-step mutants. Statistical testing for association of mutation with cross-resistance phenotype. To 327 limit the number of tests, we eliminated all events that occurred fewer than 3 times in all 328 phenotypes. We then performed two-tailed fisher exact tests to detect associations 329 between each specific mutation and cross-resistance phenotype. 330
